

Financial Statements

Of

DKMS BMST Foundation India

(Formerly known as 'BMST Stem Cell Donor Registry Foundation India')
(a company incorporated u/s. 8 of the Companies Act, 2013)

For The Year Ended

31st March 2019

DKMS BMST Foundation India

(Formerly known as 'BMST Stem Cell Donor Registry Foundation India')

(a company incorporated u/s. 8 of the Companies Act, 2013)

CIN - U74900KA2015NPL082065

Registered Office	New Thippasandra Main Road, HAL III Stage, Bangalore - 560 075 Karnataka , India
Directors	Dr.Latha Jagannathan . (Director) Mr. Prabhashankar Narayanarao Khokale (Director) Dr. Vinod Swaroop Saxena (Independent Director) Dr. Alexander Heinrich Schmidt (Independent Director) Mr. Sirko Geist (Director)
Statutory Auditors	K. G. Acharya & Co., Chartered Accountants, No. 14, Girls School Street, Kumarapark West, Seshadripuram, Bangalore - 560 020

DKMS BMST FOUNDATION INDIA

(Formerly known as BMST Stem Cell Donor Registry Foundation India)

(a company incorporated u/s. 8 of the Companies Act, 2013)

New Thippasandra Main Road, HAL III Stage, Bangalore - 560 075, Karnataka, India

Email id - contact@scrindia.org

CIN: U74900KA2015NPL082065

Ph - 080 - 2520 1155

Directors' Report

The Members,

Ladies and Gentlemen,

We have pleasure in presenting our Fourth Annual Report together with Audited Accounts of the Company for the period ended March 31, 2019.

State of Company's Affairs-- Financial Results:

The operations of the Company during the year under report were Satisfactory and the company proposes to do better during the current year.

The financial highlights of the company are provided below:

(Amount in Rs.)

For the Year Ending 31 st March	2019	2018
Donation Received	5,02,000 -	2,00,000 -
Surplus / (Deficit) for the year before depreciation	2,30,054 -	(1,25,973)
Deduct: Depreciation	--	--
Surplus / (Deficit) for the year before tax	2,30,054 -	(1,25,973)
Deduct: Provision for Taxes	--	--
Surplus / (Deficit) for the year	2,30,054 -	(1,25,973)
Balance Brought Forward from previous year	(1,08,181) -	17,792
Balance carried to Balance Sheet	1,21,873 -	(1,08,181)

❖ **Extract of Annual Return**

Pursuant to the requirements under Section 92(3) and Section 134 (3) (a) of the Companies Act, 2013 read with the corresponding Rules, the extract of the Annual Return in Form **MGT - 9** is annexed to this Report.

❖ **Board Meetings**

During the Financial Year 2018-19 3 (Three) Meetings of the Board were conducted on the following dates -

- 14-Sep-2018
- 04-Oct-2018
- 14-Feb-2019

❖ **Director's Responsibility Statement**

Pursuant to the requirement under Section 134 (3) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- (a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- (b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the Surplus of the company for that period;
- (c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) the directors have prepared the annual accounts on a going concern basis; and
- (e) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

❖ **Conservation of Energy, Technology Absorption & Foreign Exchange Earnings & Outgo:**

(A) Conservation of Energy –

- (i) The Company has not taken any special measures for conservation of energy and hence, its impact on the Company is Nil.
- (ii) The company has not taken any special measures for utilizing alternate sources of energy.
- (iii) The Company has not made any Capital Investment on Energy Conservation Equipment.

(B) Technology absorption –

- (i) The Company is not required to absorb any new technology.
- (ii) The Company has not imported any Technology during the year under review.
- (iii) The Company has not incurred any expenditure on Research & Development during the year.

(C) Foreign Exchange earnings and outgo –

Particulars	Y.E 31.03.2019	Y.E 31.03.2018
a) Expenditure incurred in Foreign Currency - Office Expenses	Nil	39,881
b) Income in Foreign Currency	Nil	Nil

❖ **Disclosure under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013**

The Company has always believed in providing a safe and harassment free workplace for every individual working in the Company through various training, awareness and practices. The Company always endeavors to create and provide an environment that is free from discrimination and harassment including sexual harassment.

There were no Employees on the rolls of the Company during the year under review.

❖ **Risk Management Policy**

The Board has formulated and implemented a Risk Management Policy for the company. There are no elements of risk which in the opinion of the Board may threaten the existence of the company.


❖ **Internal Financial Control**


The directors had laid down Internal Financial Controls with reference to the Financial Statements to be followed by the company and such internal financial controls were in place during the FY 2018-19 and are adequate.

❖ **Acknowledgements**

Your Directors wish to place on record their deep appreciation and gratitude for co-operation and assistance extended to the Company by the Shareholders during the year.

For and on behalf of the Board
For **DKMS BMST Foundation India**
(formerly known as BMST Stem Cell Donor Registry Foundation India)


Dr. Latha Jagannathan
Director
DIN: 00176248


Mr. Prabhashankar K N
Director
DIN: 01499577

Bangalore

19-09-2019

Enclosures:

1. MGT - 9
2. Statement on declaration given by independent directors U/s. 149(6)

Form No. MGT-9**EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31-03-2019**

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

(i)	CIN	U74900KA2015NPL082065
(ii)	Registration Date	6 th August, 2015
(iii)	Name of the Company	M/s. DKMS BMST Foundation India (formerly known as BMST Stem Cell Donor Registry Foundation India)
(iv)	Category / Sub category of the Company	Company Limited by Shares / Indian Non – Government Company.
(v)	Address of Registered office & contact details	New Thippasandra Main Road, HAL III Stage, Bangalore - 560 075, Karnataka, India
(vi)	Whether listed company	No
(vii)	Name, Address and Contact details of Registrar and Transfer Agent, if any	NA

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10 % or more of the total turnover of the company shall be stated – Not Applicable

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S. No.	Name & Address of the Company	CIN / GLN	Holding / Subsidiary / Associate	% of shares held	Applicable Section
1.	DKMS Gemeinnützige GmbH	-	Holding Co.	75%	2(87)(ii)

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

(i) Category-wise Share Holding

[illegible]

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
(2) Non-Institutions									
a. Bodies Corp									
i. Indian	-	-	-	-	-	-	-	-	-
ii. Overseas									
b. Individuals	-	-	-	-	-	-	-	-	-
i) Individual shareholders holding nominal Share capital upto Rs. 1 lakh	-	-	-	-	-	-	-	-	-
ii) Individual shareholders holding nominal Share capital in excess of Rs. 1 lakh	-	-	-	-	-	-	-	-	-
c. Others (Specify)	-	-	-	-	-	-	-	-	-
Sub-Total (B)(2)	-	-	-	-	-	-	-	-	-
Total Public Share Holding (B)=(B)(1)+(B)(2)	-	-	-	-	-	-	-	-	-
C. Shares held by Custodian for GDR & ADR	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	-	10,000	10,000	100%	-	2,00,000	2,00,000	100%	-

(ii) Shareholding of Promoters

Sl No.	Share Holders Name	Shareholding at the beginning of the year			Share holding at the end of the year			% Change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1.	Bangalore Medical Services Trust through Mr. Prabhashankar Narayanarao Khokale	2,500	25%	-	50,000	25%	-	-
2.	DKMS gemeinnützige GmbH	7,500	75%		1,50,000	75%		-
Total		10,000	100%	-	2,00,000	100%	-	-

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl No.		Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the company	No. of Shares	% of total Shares of the company
Bangalore Medical Services Trust through Mr. Prabhashankar Narayanarao Khokale					
1.	At the beginning of the year	2,500	25%	2,500	25%
2.	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease Rights Issue on 04.10.2018	47,500	-	50,000	-
3.	At the End of the year	50,000	25%	50,000	25%
DKMS gemeinnützige GmbH					
1.	At the beginning of the year	7,500	75%	7,500	75%
2.	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease Rights Issue on 04.10.2018	1,42,500	-	1,50,000	-
3.	At the End of the year	1,50,000	75%	1,50,000	75%

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs)- Nil**(v) Shareholding of Directors and Key Managerial Personnel:**

Sl No.	For Each of the Directors and KMP	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the company	No. of Shares	% of total Shares of the company
Bangalore Medical Services Trust through Mr. Prabhashankar Narayanarao Khokale					
1.	At the beginning of the year	2,500	25%	2,500	25
2.	Date wise Increase / Decrease in Promoters Share holding during the year specifying the reasons for increase / decrease Rights Issue on 04.10.2018	47,500	-	50,000	-
3.	At the End of the year	50,000	25%	50,000	25%

V. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment - Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL - Nil**VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES - Nil**



INDEPENDENT AUDITOR'S REPORT

To the Members **DKMS BMST Foundation India**
(Formerly known as BMST Stem Cell Donor Registry Foundation India)

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **DKMS BMST Foundation India** (formerly known as BMST Stem Cell Donor Registry Foundation India) ("the Company"), which comprise the Balance Sheet as at March 31, 2019, the Statement of Income & Expenditure, the Cash Flow Statement for the Year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act ('The Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of state of affairs of the Company as at 31st March 2019 and Surplus and its cashflows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified U/s. 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the financial statements and auditors' report thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors' Report and its Annexures but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.



Responsibilities of Management's and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rule, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- (a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



- (d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. This report does not include a statement on the matters specified in paragraphs 3 of the Companies (Auditor's Report) Order, 2016, issued by the Central Government of India, in terms of sub-section (11) of section 143 of the Act, since in our opinion and according to the information and explanations given to us, the said Order is not applicable to the company.

2. As required by Section 143(3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c. The Balance Sheet and the Statement of Income and Expenditure dealt with by this Report are in agreement with the books of account.
- d. In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors as on 31st March, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164(2) of the Act.



With respect to the adequacy of the Internal Financial Controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in '**Annexure - A**'

- g. With respect to the other matters to be included in the Auditor's Report in accordance

- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us"
- i) the company does not have any pending litigations which would impact its financial position;
 - ii) the company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the company.

For M/s. K G Acharya & Co.,
Chartered Accountants

FRN 0080196

Sunitha Jain
Partner

M. No. 227400



Bangalore

19-09-2019

UDIN: 19227K00 AAAADN6507

Annexure – A To The Independent Auditor's Report Of Even Date On The Financial Statements Of DKMS BMST Foundation India (formerly known as BMST Stem Cell Donor Registry Foundation India)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the Internal Financial Controls over financial reporting of DKMS BMST Foundation India (formerly known as BMST Stem Cell Donor Registry Foundation India) ("the Company") as of March 31, 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to Financial Statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's Internal Financial Controls over Financial Reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate Internal Financial Controls Over Financial Reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the Internal Financial Controls with reference to Financial Controls Over Financial Reporting and their operating effectiveness. Our audit of Internal Financial Controls Over Financial Reporting included obtaining an understanding of Internal Financial Controls Over Financial Reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's Internal Financial Controls with reference to financial statements.



Meaning of Internal Financial Controls with Reference to Financial Statements.

A company's internal financial controls with reference to financial Statement is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial Statements includes those policies and procedures that:

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of with reference to financial Statement

Because of the inherent limitations of internal financial controls with reference to financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate Internal Financial Controls with reference to financial Statements and such Internal Financial Controls with reference to Financial Statements were operating effectively as at March 31, 2019, based on the internal control with reference to Financial Statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Bangalore

19-09-2019


UDIN: 19227400AAAA DN6507

For M/s. K G Acharya & Co.,
Chartered Accountants

FRN 008019S

Sunitha Jain
Partner

M. No. 227400



DKMS BMST FOUNDATION INDIA (Formerly known as BMST Stem Cell Donor Registry Foundation India)

(A Company incorporated Under Sec. 8 of the Companies Act, 2013)

Balance Sheet as at 31st March 2019

(Amount in ₹)

Particulars		Note No.	As at 31.03.2019	As at 31.03.2018
I EQUITY AND LIABILITIES				
1) Shareholders' funds				
(a) Share Capital	1	20,00,000	1,00,000	
(b) Corpus Fund	2	1,00,000	1,00,000	
(c) Reserves & Surplus	3	1,21,873	(1,08,181)	
Total		22,21,873	91,819	
II ASSETS				
1) Non Current Assets				
(a) Long-term Loans and Advances	4	3,000	3,000	
2) Current Assets				
(a) Cash and Bank Balances	5	22,18,873	88,819	
Total		22,21,873	91,819	

Significant Accounting Policies & Other Explanatory
Information forming part of the financials statements

7

Subject to our report of even date attachedFor **M/s. K. G. Acharya & Co.,****Chartered Accountants****FRN. 008019S****Sunitha Jain**

Partner

M.No. 227400

**Bangalore****19-Sep-2019****UDIN: 19227400 AAAADN6507**

For and on behalf of the Board of

DKMS BMST FOUNDATION INDIA

(Formerly known as BMST Stem Cell Donor Registry Foundation India)

CIN : U74900KA2015NPL082065

Dr. Latha Jagannathan

Director

DIN : 00176248

Mr. Prabhaskar K N

Director

DIN : 01499577

DKMS BMST FOUNDATION INDIA (Formerly known as BMST Stem Cell Donor Registry Foundation India)

(A Company incorporated Under Sec. 8 of the Companies Act, 2013)

Statement of Income & Expenditure for the Year 01.04.2018 to 31.03.2019

(Amount in ₹)

Particulars		Note No.	YE 31.03.2019	YE 31.03.2018
I.	Revenue from operations		-	-
II.	Donations Received		5,02,000	2,00,000
III.	Total Revenue	(I + II)	5,02,000	2,00,000
IV.	Expenses:			
	Other Expenses	6	2,71,946	3,25,973
	Total expenses	IV	2,71,946	3,25,973
V.	Excess of Income over Expenditure	III - IV	2,30,054	(1,25,973)
VI.	Tax Expense		-	-
VII.	Surplus / (Deficit) for the Year	V - VI	2,30,054	(1,25,973)
VIII.	Basic Earnings per Equity Share of Face Value Rs.10/- each		2.23	(26.67)

Significant Accounting Policies & Other Explanatory
Information forming part of the financial statements

7

Subject to our report of even date attached
For M/s. K. G. Acharya & Co.,
Chartered Accountants
FRN. 008019S

For and on behalf of the Board of

DKMS BMST FOUNDATION INDIA

(Formerly known as BMST Stem Cell Donor Registry Foundation India)

CIN : U74900KA2015NPL082065


Sunitha Jain

Partner

M.No 227400



Dr. Latha Jagannathan

Director

DIN : 00176248

Mr. Prabhashankar K N

Director

DIN : 01499577

Bangalore

19-Sep-2019

UDIN: 19227400AAAA DN6507

DKMS BMST FOUNDATION INDIA (Formerly known as BMST Stem Cell Donor Registry Foundation India)

(A Company incorporated Under Sec. 8 of the Companies Act, 2013)

Cash Flow Statement for the Year 01.04.2018 to 31.03.2019

(Amount in ₹)

Particulars	31.03.2019 ₹	31.03.2018 ₹
A) Cash Flow From Operating Activities		
Surplus/Deficit	2,30,054	-1,25,973
Add: ROC fees for Increase in Authorised Share Capital	2,01,000	-
Operating profit before working capital changes	4,31,054	-1,25,973
Adjustments for increase/decrease in- Other payables	-	-
Cash generated from operating activities	4,31,054	(1,25,973)
Taxes paid (net of refunds)	-	-
Net cash generated from operating activities (A)	4,31,054	(1,25,973)
B) Cash Flow From Investing activities		
Net cash applied in investing activities (B)	-	-
C) Cash Flow From Financing Activities		
Increase in Share Capital	19,00,000	99,800
Add: ROC fees for Increase in Authorised Share Capital	(2,01,000)	-
Net cash generated from financing activities (C)	16,99,000	99,800
D) Net increase in cash and cash equivalents (A + B + C)	21,30,054	-26,173
E) Opening Cash and cash equivalents	88,819	1,14,992
F) Closing Cash and cash equivalents (D + E)	22,18,873	88,819

Significant Accounting Policies & other explanatory information forming part of the financial statements

Subject to our report of even date attached

For M/s. K. G. Acharya & Co.,
Chartered Accountants

FRN. 008019S

Sunitha Jain
Partner

M.No 227400

Bangalore

19-Sep-2019

UDIN : 19227400AAAADN6507

For and on behalf of the Board of

DKMS BMST FOUNDATION INDIA

(Formerly known as BMST Stem Cell Donor Registry Foundation India)

Dr. Latha Jagannathan
Director

DIN : 00176248

Mr. Prabhashankar K N
Director

DIN : 01499577

Notes:**1. Cash and Cash Equivalents consist of cash on hand and balance with banks**

	As at 31.03.19	As at 31.03.18
Cash on Hand	-	-
Balances with Bank in Current Account	22,18,873	88,819
Total	22,18,873	88,819

2. The Cash Flow Statement has been prepared under "Indirect Method" pursuant to the requirements of AS - 3 - "Cash Flow Statement" as notified under Section 133 r/w rule 7 of Companies (Accounts) Rules 2014.

Notes to Balance Sheet				(Amount in ₹)	
Note No. 1					
Share Capital		As at 31.03.2019		As at 31.03.2018	
		Numbers	Amount	Numbers	Amount
Authorized Share Capital					
Equity Shares of Rs. 10 each		10,00,000	1,00,00,000	10,000	1,00,000
Issued, Subscribed & Paid up					
Equity Shares of Rs. 10 each		2,00,000	20,00,000	10,000	1,00,000
Additional Disclosures (also see note 7.6)					
(a) Reconciliation of number of shares outstanding at beginning and end of the reporting period					
At the beginning of the year	10,000	1,00,000	20	200	
Add: Allotment made during the year	1,90,000	19,00,000	9,980	99,800	
At the end of the period	2,00,000	20,00,000	10,000	1,00,000	
(b) Shares held by Holding Company					
DKMS gemeinnützige GmbH, Germany	1,50,000	15,00,000	7,500	75,000	
(c) Shares held by Shareholders holding more than 5% Shares					
Bangalore Medical Services Trust through Mr. Prabhashankar	50,000	5,00,000	2,500	25,000	
DKMS gemeinnützige GmbH, Germany	1,50,000	15,00,000	7,500	75,000	
Particulars		As at 31.03.2019		As at 31.03.2018	
Note No. 2					
Corpus Fund					
Opening Balance		1,00,000		1,00,000	
Add: Contributions received towards Corpus Fund		-		-	
		1,00,000		1,00,000	
Note No. 3					
Reserves and Surplus					
Surplus - Income & Expenditure account (*)		1,21,873		(1,08,181)	
		1,21,873		(1,08,181)	
(*) Surplus / (Deficit) in Income & Expenditure account					
Opening Balance		(1,08,181)		17,792	
Add: Surplus / (deficit) for the Year		2,30,054		(1,25,973)	
		1,21,873		(1,08,181)	



Notes to Balance Sheet			(Amount in ₹)
Particulars	As at 31.03.2019	As at 31.03.2018	
Note No. 4			
Long-term loans and advances (Unsecured, Considered Good)			
Security Deposits	3,000	3,000	
	3,000	3,000	
Note No. 5			
Cash and Bank Balances			
Cash and Cash Equivalents			
<i>Cash in hand</i>	-	-	
<i>Balances with Banks - in Current Accounts</i>	22,18,873	88,819	
	22,18,873	88,819	



Notes Forming Part of Statement of Income & Expenditure			(Amount in ₹)
Particulars	YE 31.03.2019	YE 31.03.2018	
Note No. 6			
Other Expenses			
Payment to Auditors -			
- as Auditors	35,400	29,500	
- for Tax Matters	8,850	5,900	
Professional and Consultancy charges	7,500	59,700	
Rates & Taxes	2,16,930	29,300	
Bank Charges	3,266	265	
Conveyance	-	1,24,652	
Printing and Stationery	-	33,775	
Office Expenses	-	42,881	
	2,71,946	3,25,973	



Note No. 7

Significant Accounting Policies and Other Explanatory Information forming part of the Financial Statements for the period ended 31st March 2019 of DKMS BMST Foundation India (Formerly known as BMST Stem Cell Donor Registry Foundation India)

About the Company

DKMS BMST Foundation India (formerly known as BMST Stem Cell Donor Registry Foundation India) was incorporated on 6th August 2015 under sec. 8 of the Companies Act 2013 with the following main objectives –

- a. To help and support people suffering from blood cancer and other diseases of the blood producing or hematopoietic system, in particular to those diseases for which an unrelated stem cell transplant is an appropriate treatment and to support such patients, directly or indirectly, including development of treatment facilities and providing guidance and advice.
- b. To set up a stem cell donor center and/or registry in India and to give people an opportunity to register as potential blood stem cell donor at public donor drives, company drives and/or through internet. To maintain a personalized database of registered potential/actual donors, including contact information, tissue characteristics as well as their medical and personal information in an anonymous format available for worldwide donor search through national/ international donor registries and further to recruit, consent and advise potential blood stem cell donors, collecting biological samples and arranging for high resolution typing and other medical laboratory tests as well as handling/ responding requests of potential donors/ patients, coordinating logistics, collection and international transportation of bone marrow or blood stem cell products and monitoring short and long term health of donors post-donation.
- c. To inform public about blood cancer and other diseases of blood producing system and to promote awareness about stem cell transplantation as a mode of treatment for patients suffering from these diseases and to inform the public about the need for voluntary and unpaid stem cell donors by way of conducting publicity drives, training, awareness and advertising campaigns in particular by using print materials, internet, social media and / or radio and television.
- d. To support other non-profit organizations, financially as well as non-financially, which fulfill the same or similar objects and to cooperate with other donor centers, stem cell registries, laboratories, transplant centers and collection centers as well as other organizations in the field of stem cell transplantation in order to promote these objectives. To subscribe to, become member of and co-operate with any association whether incorporated or not whose objects are similar to those contained in this memorandum. This will include organizations such as World Marrow Donor Associations and Bone Marrow Donor Worldwide.



Note No. 7**Significant Accounting Policies and Other Explanatory Information forming part of the Financial Statements for the period ended 31st March 2019 of DKMS BMST Foundation India** (Formerly known as BMST Stem Cell Donor Registry Foundation India)**About the Company**

DKMS BMST Foundation India (formerly known as BMST Stem Cell Donor Registry Foundation India) was incorporated on 6th August 2015 under sec. 8 of the Companies Act 2013 with the following main objectives –

- a. To help and support people suffering from blood cancer and other diseases of the blood producing or hematopoietic system, in particular to those diseases for which an unrelated stem cell transplant is an appropriate treatment and to support such patients, directly or indirectly, including development of treatment facilities and providing guidance and advice.
- b. To set up a stem cell donor center and/or registry in India and to give people an opportunity to register as potential blood stem cell donor at public donor drives, company drives and/or through Internet. To maintain a personalized database of registered potential/actual donors, including contact information, tissue characteristics as well as their medical and personal information in an anonymous format available for worldwide donor search through national/ international donor registries and further to recruit, consent and advise potential blood stem cell donors, collecting biological samples and arranging for high resolution typing and other medical laboratory tests as well as handling/ responding requests of potential donors/ patients, coordinating logistics, collection and international transportation of bone marrow or blood stem cell products and monitoring short and long term health of donors post-donation.
- c. To inform public about blood cancer and other diseases of blood producing system and to promote awareness about stem cell transplantation as a mode of treatment for patients suffering from these diseases and to inform the public about the need for voluntary and unpaid stem cell donors by way of conducting publicity drives, training, awareness and advertising campaigns in particular by using print materials, internet, social media and / or radio and television.
- d. To support other non-profit organizations, financially as well as non-financially, which fulfill the same or similar objects and to cooperate with other donor centers, stem cell registries, laboratories, transplant centers and collection centers as well as other organizations in the field of stem cell transplantation in order to promote these objectives. To subscribe to, become member of and co-operate with any association whether incorporated or not whose objects are similar to those contained in this memorandum. This will include organizations such as World Marrow Donor Associations and Bone Marrow Donor Worldwide.



7.1 Significant accounting policies

a. Basis of preparation of financial statements

The financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (Indian GAAP) under the historical cost convention on accrual basis. GAAP comprises mandatory Accounting Standards as specified under Sec. 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014. Accounting policies have been consistently applied except where a newly issued Accounting Standard is initially adopted or a revision to an existing Accounting Standard requires a change in the accounting policy hitherto in use.

b. Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures of contingent liabilities at the date of the financial statements and reported amounts of income and expenses during the year.

Management believes that the estimates used in the preparation of financial statements are prudent and reasonable. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Difference, if any, between the actual results and estimates are recognized in the period in which the results are known / materialized.

c. Cash Flow statement

Cash flows are reported using the indirect method, whereby excess of Expenditure over Income before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

d. Recognition of Income and Expenditure

General Grants and Donations are recognized in the year in which they are received.


Contributions received with specific directions that they must form part of the Corpus are recognized in the Balance Sheet under Equity & Liabilities under Corpus Fund.

Other Items of Income and Expenditure are recognized on accrual basis.

e. Foreign Currency Translation/ Transaction

Transaction in foreign currencies is recorded at the exchange rate prevailing on the date of the transaction.

Foreign currency denominated monetary assets and liabilities are translated into the functional currency at exchange rates in effect at the end of each reporting period.



Foreign exchange gains or losses arising from settlement and translations are recognized in the statement of profit or loss.

Non-monetary assets and non-monetary liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevailing at the date of transaction.

f. Earnings per share (EPS)

Basic EPS is computed by dividing the net profit after tax by the weighted average number of equity shares outstanding during the year.

g. Income Taxes

Tax on income for the current period is determined based on taxable income and tax credits computed in accordance with the provisions of the Income Tax Act, 1961 and based on the expected outcome of assessments/appeals.

Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the Company will pay normal income tax. Accordingly, MAT is recognized as an asset in the Balance Sheet when it is probable that future economic benefit associated with it will flow to the Company.

Deferred tax is recognized on timing differences between the incomes accounted in financial statements and the taxable income for the year, and quantified using the tax rates and laws enacted or substantively enacted as on the Balance Sheet date.

Deferred tax assets relating to unabsorbed depreciation/business losses/losses under the head capital gains are recognized and carried forward to the extent there is virtual certainty, supported by convincing evidence, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

Other deferred tax assets are recognized and carried forward to the extent that there is a virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized.

7.2 Earnings / Expenditure incurred in Foreign Currency

Particulars	(Amount in ₹)	
	Y.E. 31.03.2019	Y.E. 31.03.2018
a) Expenditure incurred in Foreign Currency		
- Office Expenses	Nil	39,881
b) Income in Foreign Currency	Nil	Nil

7.3 There were no employees on rolls of the company. As such the company has not made any provision arising as per the "The Payment of Gratuity Act".



7.4 Disclosure in respect of Related Parties transactions as per Accounting Standard 18 – Related Party Disclosure for the year ended 31st March, 2019 is as given below:

- (a) List of related parties
- over which control exists – Nil
 - Who exercise control –

Relationship	Name of the Related Party
Holding Company	• DKMS Gemeinnützige GmbH
Key Management Personnel (KMP)	• Dr. Latha Jagannathan
Enterprise which exercises significant influence	• Bangalore Medical Services Trust through Mr. Prabhashankar Narayanarao Khokale

- (b) Names of the Related Parties with whom transactions were carried out during the year and description of relationship.

Relationship	Name of the Related Party
Holding Company	• DKMS Gemeinnützige GmbH
Enterprise which exercises significant influence	• Bangalore Medical Services Trust through Mr. Prabhashankar Narayanarao Khokale

- (c) Summary of Transactions with the Related Parties for the Previous Year –
(Amount in ₹)

Particulars	FY 2018-19		FY 2017-18	
	Enterprise which exercises significant influence	Holding Company	Enterprise which exercises significant influence	Holding Company
Contribution to Equity Capital	4,75,000	14,25,000	24,800	75,000

- (d) Balances payable

(Amount in ₹)

Particulars	Enterprise which exercises significant influence		Holding Company	
	2018-19	2017-18	2018-19	2017-18
Contribution to Equity Capital	5,00,000	25,000	15,00,000	75,000

- 7.5** The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards specified under Sec. 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.

7.6 Rights and Restrictions attached to Equity Shares

The Company has one class of equity shares having a par value of ₹ 10/- each. Each shareholder is eligible for one vote per share held. As per the provisions of Section 8 of the Companies Act, 2013 distribution of dividends to shareholders is prohibited. Further the shareholders are not entitled to the assets of the company on liquidation.



7.7 Basic Earnings per Share computed in accordance with AS 20: Earnings per Share:

Particulars	FY 2018-19	FY 2017-18
Surplus/(Deficit) after tax as per Accounts	2,30,054	(1,25,973)
Weighted average number of shares outstanding	1,03,178	4,723
Basic EPS (₹)	2.23	(26.67)

7.8 Dues to micro & small enterprises

The Company has no dues to micro and small enterprises during the period ended 31st March 2019 & 31st March 2018.

7.9 Paises have been rounded off to nearest rupee and due to this rounding off, the numbers presented throughout the document may not add up precisely to the totals and percentages may not precisely reflect the absolute figures**7.10** Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

Subject to our report of even date
For M/s. K G Acharya & Co.,
Chartered Accountants
 FRN 008019S

Sunitha Jain
 Partner
M. No. 227400



For and on behalf of the Board
DKMS BMST Foundation India
 (formerly known BMST Stem Cell Donor Registry Foundation India)
 CIN : U74900KA2015NPL082065

Dr. Latha Jagannathan
 Director
DIN :00176248

Mr. Prabhashankar K N
 Director
DIN :01499577

Bangalore
19-09-2019

UDIN: 19227400AAADN6507

Non - Statutory Details

Of

DKMS BMST Foundation India

(Formerly known as 'BMST Stem Cell Donor Registry Foundation India')
(a company incorporated u/s. 8 of the Companies Act, 2013)

For The Year Ended

31st March 2019

Groupings To Balance Sheet			
Particulars	As at 01.04.2018 (No's)	Transfers / Allotments during the year	As at 31.03.2019 (No's)
Share Capital			
Bangalore Medical Services Trust through Mr. Prabhashankar K N	2,500	47,500	50,000
DKMS gemeinnützige GmbH, Germany	7,500	1,42,500	1,50,000
	10,000	1,90,000	2,00,000
(Amount in ₹)			
Particulars	As at 31.03.2019	As at 31.03.2018	
Security Deposits			
Telephone Deposit	3,000	3,000	
	3,000	3,000	
Balances with Banks - in Current Accounts			
The Oriental Bank of Commerce	7,21,814	14,084	
HSBC Bank - FCRA Account - 073-190209-001	14,97,252	74,735	
HSBC Bank - FCRA Utilisation Account - 073-190209-002	(193)	-	
HSBC Bank - Domestic Account - 073-190209-003	-	-	
	22,18,873	88,819	



Groupings to Statement of Income and Expenditure		
Particulars	YE 31.03.2019	YE 31.03.2018
<u>Professional and Consultancy charges</u>		
CS Kempe Gowda	7,500	12,800
K Tara Acharya	-	11,500
D Prasanna & Co.	-	35,400
	7,500	59,700
<u>Rates & Taxes</u>		
Income Tax & ROC Filing fees	15,930	29,300
ROC fees for Increase in Authorised Share Capital	2,01,000	-
	2,16,930	29,300
<u>Office Expenses</u>		
In Indian Currency	-	3,000
In Foreign Currency	-	39,881
	-	42,881



A.Y. 2019-2020

Name : DKMS BMST Foundation India

P. Y. : 2018-2019

Address : New Thippasandra Main Road
HAL III Stage, Bangalore - 560 075

P.A.N. : AAGCB 4824 Q

D.O.F. : 06-Aug-2015

Status : Trust

Statement of Income

	Sch.No	Rs.	Rs.	Rs.
Taxable Income u/s 11 to 13	1			0
■ Total Income				0
Tax on total income				0

Schedule 1

Taxable Income u/s 11 to 13

Return to be furnished u/s 139(4A)

Whether registered u/s 12A / 12AA? Yes

Whether approved u/s 10(23C) (iv) to (via)? No

Aggregate income referred to in sections 10, 11 & 12 5,02,000

Income available for application u/s 11 5,02,000

- 11(1): applied in India during the PY

- Revenue account 2,71,753

- 11(2): Amount accumulated for specified purpose

Amount set apart 1,54,947 1,54,947

- 11(1): Accumulation to the extent of 15% 75,300 5,02,000

Income after application 0

Total deemed income


Taxable income 0

Bank A/c: Oriental Bank of Commerce 09851131002507 IFSC: ORBC0100985

Date : 18-Sep-2019

Place : Bangalore

For DKMS BMST Foundation India

 Latha
Authorised Signatory

Statement Of Total Income
Of
DKMS BMST FOUNDATION INDIA
(Formerly known as BMST Stem Cell Donor Registry Foundation India)

New Thippasandra Main Road, HAL III Stage, Bangalore - 560 075, Karnataka, India

PAN:	AAGCB 4824 Q	Assessment Year :	2019 - 2020
Date of Registration:	06-August-2015	Financial Year :	01-04-18 to 31-03-19
Nature of business:	Support Blood Cancer patients and set up Stem Cell Donor Center		
Status:	Domestic Company in which public are not substantially interested (Sec 8 Company)		
			₹
Gross Total Income			5,02,000
85% to be Expensed during the FY 2017-18			4,26,700
Less : Expenses			2,71,946
Gross Total Income			1,54,754
Less : Invested U/s 11(5) (Note - 1)			1,54,754
Total Income			-
Income Tax Payable			-

Note - 1

Sec. 11 - Income from property held for charitable or religious purposes

(2) - Where 85% of the income referred to S. 11(1)(a) or (b) is not applied to charitable or religious purposes in India during the previous year but is accumulated or set apart, either in whole or in part, for application to such purposes in India, such income so accumulated or set apart shall not be included in the total income of the previous year of the person in receipt of the income, provided the following conditions are complied with, namely:—

(a) such person furnishes a statement in the Form 9A in prescribed manner to the AO, stating the purpose for which the income is being accumulated or set apart and the period for which the income is to be accumulated or set apart, which shall in no case exceed five years;

(b) the money so accumulated or set apart is invested or deposited in the forms or modes specified in sub-section (5);

(c) the statement referred to in clause (a) is furnished on or before the due date specified under sub-section (1) of section 139 for furnishing the return of income for the previous year

(5) - The forms and modes of investing or depositing the money referred to in 11(2)(b), inter alia includes -

(iii) - deposit in any account with a scheduled bank or a co-operative society engaged in carrying on the business of banking